PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1383370
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1383370
According to Stratistics MRC, the Global Digital Diabetes Management Market is accounted for $18.9 billion in 2023 and is expected to reach $52.1 billion by 2030 growing at a CAGR of 15.6% during the forecast period. Diabetes is a chronic disease that affects the body's glucose levels. This illness is mostly brought on by the pancreas' failure to make insulin or to keep the body's glucose levels stable. Devices and applications are used in diabetes care to control blood glucose levels in the body. Using these gadgets to accurately measure diabetes aids in treating patients effectively as well as recording and retaining data.
According to WHO, in 2018, the number of people suffering with diabetes has significantly risen from 108 million in 1980 to approximately 422 million in 2014. The prevalence of diabetes across the glove has increased from 4.7% to 8.5%. In 2016, around 1.6 million deaths occurred due to diabetes.
Artificial intelligence (AI) is a fast developing field, and its applications in the diagnosis and treatment of diabetes have completely changed how we approach this long-term condition. Predictive models for the likelihood of acquiring diabetes and related complications have been developed using machine learning concepts. Clinical decision support is advantageous to both patients and healthcare providers since people are given more authority to control their diabetes on their own. This is fueling market expansion.
Patients still prefer the old-fashioned ways of managing their diabetes in many places. Many patients steer clear of digital platforms in favor of conventional blood glucose monitoring due to the cheap cost and lack of knowledge about connected devices and applications. The low uptake of smartphones, tablets, and laptops for diabetes treatment in various nations has also hampered the acceptability of cutting-edge technologies. Digital diabetes therapy has been made more difficult to use because to low knowledge, a shortage of qualified workers, and poor reimbursements.
Demand for digital diabetes management devices in homecare settings is being driven by government programs to increase diabetes awareness and user-friendly insulin delivery device interfaces. The increased use of these gadgets around the globe is due to rising consumer awareness of technologically advanced items. Additionally, a significant increase in the prevalence of diabetes and several government awareness campaigns might fuel market expansion.
Comparatively fewer technologically advanced digital diabetes management platforms are used in poorer nations than in industrialized ones. This is attributed to a number of factors, including insufficient infrastructure, hazy national e-health agendas, the need to allay public concerns about data privacy and security, challenges in achieving interoperability, a shortage of qualified health informatics professionals, and a lack of regional integration strategies. This is the element impeding market expansion.
The market for digital diabetes management devices was positively influenced by the epidemic. When patients with serious lung infections were brought to hospitals, controlling blood glucose levels became crucial. The patient's blood glucose levels significantly changed as a result of the disease-treating medications. Additionally, the Centers for Disease Control and Prevention underlined the elevated risk of admission to critical care that persons with diabetes and a COVID-19 diagnosis faced. Devices for managing diabetes become much more necessary as a result.
The continuous blood glucose monitoring system segment is expected to be the largest during the forecast period owing to its advanced features such as compatibility with smart devices that serve as display devices. This is attributed to the factors including on-going technical advancement, an increase in product introductions, more remote monitoring technology integration into devices, and expanding public awareness. The usage of this technology will make it easier to monitor a patient's blood glucose levels in real time. It also provides a complete picture of each person's blood glucose levels.
The hospitals segment is expected to have the highest CAGR during the forecast period. Hospitals can employ online resources or mobile applications that provide patients diabetes information, self-management tools, and support. With the use of these technologies, patients may have a better understanding of their health, track their blood sugar levels, manage their medication, and receive guidance from medical professionals.
North America is projected to hold the largest market share during the forecast period aided by the availability of advanced technologies and the recent approval of many digital blood glucose patient monitoring devices. Favorable reimbursement guidelines and governmental assistance further fuel industry expansion. Additionally, collaborations between IT firms and healthcare providers help the industry grow.
Asia Pacific is projected to hold the highest CAGR over the forecast period. This market is expected to develop as a result of a variety of factors, including an increase in the number of individuals with diabetes, growing healthcare costs, and an increase in the number of market competitors in the area. The expanding health awareness of diabetes and the other linked health issues, as well as the region's rising disposable income, are additional factors projected to support the expansion of this regional market.
Some of the key players in Digital Diabetes Management market include: Sanofi, Medtronic, Abbott Laboratories, Bayer AG, Insulet Corporation, Dexcom, Inc., F. Hoffmann-La Roche Ltd., Johnson and Johnson, B. Braun Melsungen AG, LifeScan, Inc., Terumo corporation., Ascensia Diabetes Care Holdings AG, Novo Nordisk A/S, AGaMatrix , Care Innovaions, LLC, Tandem Diabetes, DarioHealth Corporation and Decide Clinical Software GmbH.
In May 2023, Medtronic plc, a global leader in healthcare technology, announced definitive agreements for the acquisition of EOFlow Co. Ltd., manufacturer of wearable insulin patches to offer the benefits of automated insulin delivery and simplify diabetes treatment.
In April 2023, Glooko, Inc., a prominent software company, inked a Global partnership deal with Hedia, an insulin dosing algorithm company, to offer an interoperable solution that integrates remote patient monitoring, connected care, and digital therapeutic technologies to increase access to people with Type 1 and Type 2 diabetes in need of bolus insulin dosing advice.
In February 2023, Dexcom launched Dexcom G7 CGM device in the US and is planning to launch in Europe and Asia Pacific by first quarter of 2024.